Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year
Image depicts PSMA PET scans of eight patients with exceptional responses from investigator-sponsored Phase 2 study
WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of 177Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum Cancer Centre in Melbourne, Australia, was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the “Image of the Year.” The image depicts the positron emissions tomography (PET) scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment.
“This recognition reflects the potential of 177Lu-PSMA-617 and radioligand therapies to be a new treatment modality for patients with metastatic castration-resistant prostate cancer (mCRPC).” said Mike Sherman president and CEO of Endocyte. “We are grateful to SNMMI for this award and to Dr. Michael Hofman for his work with 177Lu-PSMA-617. We are continuing to enroll patients with mCRPC in the Phase 3 VISION trial to confirm the promising results seen in earlier trials.”
Dr. Hofman, a clinical investigator in the study, said, “recognition of this image as Image of the Year underscores the potential impact that targeting 177Lu to PSMA-positive disease has had in these patients. This recognition encourages us to continue our research at Peter MacCallum Cancer Centre in a 50-patient single arm Phase 2 study and the 200 patient TheraP Phase 2 study.”
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a721f857-695c-47cb-bca2-93615ac49880
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, in phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Forward Looking Statements
© 2018 GlobeNewswire, Inc. All Rights Reserved.